US$ 21.12
glp-1/gip agonists The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Targeting GLP-1, GIP & GCG
Description
Ongoing support improves adherence and outcomes

Answer our Poll: Would you ever use a weight loss drug like Ozempic

Newsome PN, Ambery P

Both companies are testing oral GLP-1 drugs
